Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Global Health

Basis to Aid Crisis: Favipiravir Oral Solution for Hospital Compounding During COVID-19 Drug Shortage

Bodin Tuesuwan a, Wunlapa Mueannoob b, Promporn Jannongtanachob b, Ariya Khunvichib a, Chiravi Pavitrapoke b, Kawinthida Wongpakdee c, Supasil Sra-iumc a, Nithi Mahanondc a, Vorasit Vongsutilers a, *

a Department of Food and Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, 10330, Thailand
b Medica Innova Co., Ltd., Bangkok, 10310, Thailand
Chulabhorn Hospital, Chulabhorn Royal Academy, Bangkok, 10210, Thailand

* Corresponding author at: Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, 10330, Thailand
E-mail address: Vorasit.v@chula.ac.th (V. Vongsutilers).

ABSTRACT

The COVID-19 pandemic outbreak has been overwhelming the healthcare system worldwide. A rapidly growing number of younger pediatric patients in Thailand necessitated the formulation of favipiravir, the most locally accessible antiviral agent against COVID-19, into a child-friendly dosage form as a safer alternative to a dispersion of crushed tablets in simple syrup. While striving to quickly develop a liquid formulation that is feasible for any local hospital production units, an oral solution was chosen due to its simplicity. Despite the large dose and poor aqueous solubility of favipiravir, a combination of pH control and use of poloxamer as a solubilizing agent has enabled us to streamline the manufacturing process of a 200 mg/15 mL oral solution for hospital compounding. To ensure its efficacy and safety, a specification for quality control was also established in accordance with the ICH quality guidelines and USP. The finished product stability was subsequently demonstrated under the conditions of 5°C ± 3°C, 25°C ± 2°C/75% RH ± 5% RH, 30°C ± 2°C/75% RH ± 5% RH, and 40°C ± 2°C/75% RH ± 5% RH. The results indicated that our formulation can be stored at 30°C ± 2°C/75% RH for 30 days, which will very well serve the need to allow drug distribution and patient use during the crisis, while the shelf-life can be extended to 60 days when stored at 5°C ± 3°C. Thus, accessibility to an essential medical treatment has been successfully enhanced for pediatric patients in Thailand and neighboring countries during the COVID-19 outbreak.

© 2022 American Pharmacists Association. Published by Elsevier Inc. All rights reserved.

INTRODUCTION

The pandemic outbreak of COVID-19 caused by SARS-CoV2 virus has been ongoing since early 2020 and continues to overwhelm the healthcare systems of most countries worldwide beyond their capacities. The time constraints imposed by the ultrafast pace of its spread precludes the development of any antiviral medications specifically against SAR-CoV2 infections. Consequently, the idea of re-proposing a previously approved antiviral agent with SAR-CoV2 replication inhibitory potential could fulfill a pivotal role in COVID-19 treatments.

Favipiravir, 6-Fluoro-3-hydroxypyrazine-2-carboxamide, is a prodrug of favipiravir-ribofuranosyl-5′-triphosphate that has been discovered through chemical library screening for antiviral agents against influenza viruses by Toyama Chemical Co., Ltd. This drug is effective towards a wide range of influenza viruses, including A (H1N1), A(NSN1), A(H7N9), and Ebola virus, and thus, indicated for the treatments of novel or re-emerging influenza virus infections unresponsive to other anti-influenza agents, especially in Ebola disease. Its RNA-dependent RNA polymerase inhibitory activity makes favipiravir a very promising candidate in combating COVID-19. To date, favipiravir has been employed in the COVID-19 treatments in several countries. Since March 2020, this molecule has been serving as a drug of choice in Thailand and also incorporated by the Thailand Ministry of Public Health into the Guidelines on Clinical Practice, Diagnosis, Treatment, and Prevention of Healthcare-associated Infection for COVID-19. For patients weighing under 90 kg, the
loading dose is 3600 mg (in two divided doses), followed by 1600 mg per day (in two divided doses) on days 2 to 5. In contrast, the adjusted doses for patients over 90 kg are 4800 and 2000 mg per day, respectively, while pediatric patients are recommended to take 70 mg/kg/day on day 1, and 30 mg/kg/day thereafter. These regimens have been highly efficacious in mild COVID-19 cases in Thailand.

Driven by the rapid increase in pediatric cases in Thailand where only favipiravir tablets are commercially available, an urgency existed to formulate this drug into a more child-friendly dosage form so that both dosing accuracy and patient compliance could be improved over those achieved with a dispersion of crushed tablets in simple syrup. Another important factor to consider was the feasibility of the manufacturing procedure since the developed formulation would ultimately become an extemporaneous preparation for any local hospitals throughout Thailand where production facilities are extremely limited. As a result, a simple oral solution of favipiravir was established.

**Experimental**

**Materials**

The following materials were used in the formulation; favipiravir (Raghava Life Sciences Pvt. Ltd., India), poloxamer 188 (BASF Corporation, USA), aspartame (Nantong Changhai, China), propylene glycol (Dow Chemical Thailand Ltd., Thailand), methylparaben (Zhejiang Shengxiaojia, China), propylparaben (Clariant, Germany), raspberry flavor (Bush Boake Allen, Singapore), vanilla flavor (Sigmaex, Switzerland), edetate disodium (EDTA) (Carlo Erbo, Italy), sodium citrate (Weifang Ensign Industry, China), sodium hydroxide (Dominion Salt Limited, New Zealand), aspartame (Sigmadex, Switzerland), propylene glycol (HPLC grade from RCI Labscan, Thailand), triethylamine (AR grade from Merck, Germany), and phosphoric acid (AR grade from Merck, Germany) were used for HPLC analysis.

**Formulation Development of Favipiravir Oral Solution**

Due to time constraints, our efforts were focused on developing a homogeneous dosage form with a simplified manufacturing process. Favipiravir or 6-fluoro-3-hydroxypyrazine-2-carboxamide is commercially supplied as a white to light yellow powder that is sparingly soluble in acetonitrile and in methanol, while slightly soluble in water and in ethanol. We thus first experimented to obtain a suitable vehicle for a stable favipiravir oral solution. As shown in Fig. 1, favipiravir is a weak acid with a pKa of 5.1 so raising the solution pH to slightly above its pKa might be sufficient to maintain favipiravir in an aqueous medium. Citrate buffer was selected based on the pKa of citric acid at 3.1, 4.7, and 6.4. At an initial 16 mg/mL concentration of favipiravir, we found that 0.01M and 0.02M trisodium citrate could not completely dissolve this drug substance. Therefore, its solubility was enhanced through both pH adjustment with sodium hydroxide and the use of poloxamer 188 as a solubilizing agent. The best results were obtained with 0.02M trisodium citrate containing 0.07% poloxamer 188 and 0.25 mL of 1M sodium hydroxide, in which favipiravir was completely dissolved at an optimum pH of 5.79 (Table 1). To simplify dose calculations during administration, the concentration was slightly adjusted to 800 mg of favipiravir per 60 mL (13.33 mg/mL), which was confirmed to be completely soluble in 0.02M citrate buffer when pH was greater than 5.8. For the flavoring agents, aspartame was selected as a sweetener while avoiding sucrose to prevent favipiravir from salt ing. The unpleasant taste of favipiravir was further masked with sodium chloride, as well as raspberry and vanilla flavors. The commonly used methylparaben and propylparaben served as preservatives. The final formulation of favipiravir oral solution is shown in Table 2.

**Hospital Compounding**

Favipiravir oral solution was prepared on a scale of 15 L using an overhead stirrer. Favipiravir was first dissolved in a vehicle containing a buffering system (sodium citrate and sodium hydroxide) mixed with poloxamer 188, EDTA, and propylene glycol. The paraben solution was prepared by dissolving methylparaben and propylparaben in propylene glycol, and then added into the favipiravir mix, along with aspartame, sodium chloride, flavors, and colorant. The final product was a clear orange solution with a pH in the range of 5.80–6.20 and filled into 60-mL amber glass bottles. A diagram illustrating the hospital compounding process is shown in Fig. 2.

**Specifications and Quality Control Tests**

To ensure the product safety and efficacy, various quality attributes of the favipiravir oral solution were established according to The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) quality guidelines: ICH Q6A.11 Despite being uncommonly required for extemporaneous preparations, the specifications of favipiravir oral solution were also justified for subsequent use in quality control tests and stability studies, simply to reflect safety and efficacy of the formulation rather than obtaining full quality data for drug registration. The analytical methods for identification, assay, organic impurities, and antimicrobial preservative contents were developed and validated specifically for use in this study. Procedures for pH determination and microbial limit test were adopted from the USP general chapters (791) pH12 and (61) Microbiological Examination of Nonsterile Products: Microbial Enumeration Tests,13 respectively.

Identification and assay of favipiravir were performed simultaneously with the determination of organic impurities in oral solution by using an LC-20AD HPLC system (Shimadzu, Japan) and a validated reversed phase HPLC (RP-HPLC) method that was developed in our laboratory. The stationary phase was Inertsil ODS-3, 250 mm x 4.6 mm, 5 μm (Shimadzu, Japan) maintained at 45°C in a column oven. The chromatographic conditions involved gradient elution with phosphate buffer pH 3.0 (mobile phase A) and a mixture of methanol and acetonitrile at 1:1 ratio (mobile phase B). The initial mobile phase composition was maintained at 98% mobile phase A for 5 min, then changed linearly to 70% mobile phase A (5–10 min), followed by a change to 5% mobile phase A (10–12 min), and reversed back to 98% mobile phase A (12–15 min), which was maintained for 5 min for column equilibration. The total run time of 20 min per injection (10 μL) at a flow rate of 1.0 mL/min. All analytes were detected at 220 nm. A favipiravir standard stock solution was prepared by accurately weighing 6.6 mg of favipiravir DMsc reference standard using analytical balance XP26DR (Mettler, Switzerland) and

![Figure 1. Chemical structure and ionization of favipiravir.](Image)
dissolving in a 1:1 mixture of acetonitrile and water to a final concentration of 0.66 μg/mL. All samples for assay were prepared by 1:50 dilution of the oral solution with acetonitrile and water (1:1), while the samples for impurity determination were prepared by 1:20 dilution of the oral solution with the same diluent.

For antimicrobial preservative contents, a methylparaben (MP) and propylparaben (PP) standard stock solution was prepared in acetonitrile and water (1:1) at a concentration of 45 μg/mL and 5 μg/mL respectively. Samples were prepared by 1:50 dilution of the oral solution with the same diluent. MP and PP in the oral solution were quantified by RP-HPLC with an LC-20AD HPLC system (Shimadzu, Japan). The stationary phase was Inertsil ODS-3, 4.6 × 150 mm with 5μm particle size and maintained at 45°C in a column oven. The mobile phase for isocratic chromatographic conditions was composed of acetonitrile and phosphate buffer (pH 3.0) at a ratio of 40:60 and a flow rate of 1.0 mL/min. The injection volume was 10 μL, and both parabens were detected with a UV detector at 220 nm. The amounts of MP and PP in each sample were calculated using a standard comparison. pH measurement was performed by using a pH meter (Model 827 from Metrohm, Switzerland).

**Stability Study of Favipiravir Oral Solution**

The chemical stability of favipiravir in aqueous solutions was expected to be low due to the sensitivity of amide functional groups to hydrolysis. However, even a month-long shelf-life would be sufficient for an extemporaneous formulation considering its usage during a crisis. Thus, the stability of our favipiravir oral solution was investigated to identify optimum storage conditions that can provide an acceptable shelf-life according to ICH Q1A. Two hospital production batches, CRAFV018 and CRAFV019, were also evaluated in this stability study. The test solutions were exposed to four conditions, i.e., 5°C ± 3°C, 25°C ± 2°C/75% RH ± 5% RH, 30°C ± 2°C/75% RH ± 5% RH, and 40°C ± 2°C/75% RH ± 5% RH. Stability-indicating parameters, including appearance, assay, organic impurities, and pH, were then determined on days 0, 7, 14, 30, 45, and 60, while the tests for antimicrobial preservative contents and microbial limits were performed only on days 0 and 60.

**Results and Discussion**

**Formulation Development and Hospital Compounding of Favipiravir Oral Solution**

Favipiravir tablets are rapidly dissolving such that 85% or more of the labeled amount of the drug substance dissolves within 30 minutes at pH 1.2 (0.1 N HCl), pH 4.5 (acetate buffer), and pH 6.8 (phosphate buffer), hence, no potential lag time in absorption is observed. In addition, favipiravir is considered as a highly permeable drug substance with a bioavailability of 97.6%. Based on the Biopharmaceutics Classification System (BCS), the safety and efficacy of favipiravir administered as a solution should therefore be comparable to those of tablet dosage form. On the other hand, a suspension formulation would require not only additional studies on dosage form performance, including dissolution profiles, but also a rather demanding preparation process, especially for hospital compounding. Considering these fundamentals, a favipiravir oral solution would be the most promising candidate to fulfill an unmet need of pediatric patients who prefer an easy-to-take dosage form. However, the challenges of oral solution formulation are to achieve sufficient quality and a suitable shelf-life that is long enough for distribution and patient usage.

Based on the chemical structure of favipiravir, amide hydrolysis and oxidation are potential major degradation pathways. Mechanistically, hydrolysis of this compound is expected to increase at higher pH, where specific base catalysis can play an important role in amide hydrolysis. Moreover, the increased favipiravir anions can deprotonate water molecules, which further facilitate hydrolysis of amide functional groups. Therefore, solubility enhancement solely by adjusting pH could be problematic, while a combined use of

---

**Table 1**

| Trial | Composition | pH | Appearance |
|-------|-------------|----|------------|
| 1     | 64 mg of favipiravir was dissolved in 4 mL of 0.01 M trisodium citrate containing 0.1% poloxamer 188 and 0.20 mL of 1 M NaOH was then added. | 5.47 | Incompletely soluble |
| 2     | 64 mg of favipiravir was dissolved in 4 mL of 0.02 M trisodium citrate containing 0.14% poloxamer 188 and 0.25 mL of 1 M NaOH was then added. | 5.77 | Completely soluble |
| 3     | 64 mg of favipiravir was dissolved in 4 mL of 0.02 M trisodium citrate containing 0.07% poloxamer 188 and 0.25 mL of 1 M NaOH was then added. | 5.79 | Completely soluble |

The concentration of favipiravir in all trials was 16 mg/mL.
Dissolve sodium citrate in purified water.

Add sodium hydroxide solution, then stir using an overhead stirrer at 1000 rpm for 5 minutes until a clear solution is obtained.

Add poloxamer 188, then stir until a clear solution is obtained.

Add EDTA and propylene glycol (portion 1), then stir until a clear solution is obtained.

Slowly add favipiravir, then stir for 90 minutes.

Add paraben solution (in propylene glycol (portion 2)), then stir until a homogeneous solution is obtained.

Add aspartame solution, sodium chloride then stir using an overhead stirrer at 1000 rpm until a clear solution is obtained.

Add sunset yellow dye, raspberry flavor and vanilla flavor, then stir until a clear solution is obtained.

Adjust the pH to 5.80 – 6.20 with 1 N sodium hydroxide (if necessary).

Adjust the final volume to 15 L with purified water, then stir for 10 minutes.

Filter the solution through nylon cloth into a stainless-steel tank.

Fill in 60-mL amber glass bottles and label

**Figure 2.** Hospital compounding process for favipiravir oral solution.

solubilizing agent(s) and optimum pH might help balance solubility and stability of the formulation. In the pH range of 5.80-6.20 generated by a citrate buffer system in the presence of favipiravir itself, more than half of drug molecules would be in the more soluble ionized form. Moreover, propylene glycol was used to lower the dielectric constant of the vehicle, while poloxamer188 served as a surfactant that enhances the solubility of favipiravir. As a result, a 200 mg/15 mL favipiravir solution was finally obtained with the excipients commonly used in oral formulations as listed in Table 2. The actual hospital preparation appeared as a clear orange solution filled in 60-mL amber glass bottles, as shown in Fig. 4.

In terms of the manufacturing process, only laboratory-scale glassware, a 20-liter stainless steel mixing tank, and a 1000-rpm overhead stirrer were required for hospital compounding on a 15L scale. The in-process control was also simple and involved monitoring of appearance and pH. Thus, our primary goal was successfully achieved by developing a favipiravir oral solution with a simplified production process that would provide both product homogeneity and batch-to-batch consistency. More importantly, a recent pharmacokinetic comparison study has demonstrated that our 200 mg/15 mL oral solution exhibited similar pharmacokinetic profiles to those of the commercially available 200-mg favipiravir tablets. The strategies reported herein could also be modified for other nucleoside analogs, such as molnupiravir.

**Specifications and Quality Control Analyses**

The specifications of favipiravir oral solution were established and justified for use in the quality control of hospital preparation, as shown in Table 3. The quality attributes in the specifications were based on a
A set of universal tests and included appearance, identification, assay, and impurities, according to ICH Q6A. Specific tests required for favipiravir oral solution comprised of pH measurement, antimicrobial preservative contents, and microbial limit test. The acceptance criteria or limits for each test were justified based on available data of the reference favipiravir tablet, the general chapters of pharmacopeial monographs, and the ICH quality guidelines. Urgency of the crisis and a risk-based approach were also taken in consideration while justifying the specifications and acceptance criteria.

The appearance of favipiravir oral solution as a clear orange solution (Fig. 4) with raspberry flavor was the first criteria for quality control. On the basis that favipiravir raw material has already been well identified by both infrared spectroscopy and liquid chromatography, its identity in the drug product could be sufficiently confirmed based on RP-HPLC comparison with favipiravir reference standard. To ensure that the amount of active substance is in therapeutic range, the acceptance criteria for assay was set between 95.0% and 105.0% labeled amount which aligns with both the specifications of favipiravir tablets currently available in the market and the 12th International Meeting of World Pharmacopoeias (IMWP) Monographs on Favipiravir and on Favipiravir tablets published by WHO. Although the IMWP monograph has also published an assay method for favipiravir tablets by isocratic HPLC, a validated in-house HPLC method was used in this study to allow simultaneous determinations of favipiravir along with organic impurities. As discussed previously, degradation of favipiravir in an aqueous oral solution is foreseeable, possibly through hydrolysis and oxidation (Fig. 3) as observed in a forced degradation study of favipiravir raw material during analytical method validation. Hence, both individual and total organic impurities need to be monitored. For the acceptance criteria, the concept of qualification threshold in ICH Q3B, which addresses the control of degradants in drug products, was considered. Based on the loading dose of favipiravir for COVID-19 treatments in adults weighing more than 90 kg, the maximum daily dose would be 4800 mg, and thus, the ICH Q3B qualification threshold would allow a limit of individual impurities only at 0.15%. However, this limit was expanded to 1.0% in our case when considering the short-term use of this product for COVID-19 treatments. This is very well in line with the concept of less than lifetime exposure to mutagenic impurities, an even more harmful class of impurities, described in the ICH M7 guideline allowing a higher acceptable limit based on shorter treatment duration. In contrast, a limit of 2.0% for total organic impurities was applied so that the amount of favipiravir remaining in the oral solution would still be in the therapeutic range.

Since the pH of an oral solution significantly impacts both the solubility and stability of favipiravir as demonstrated during formulation development, a rather narrow limit of 5.80-6.20 was suggested. In addition, the amounts of propylparaben and methylparaben were controlled under the antimicrobial preservative contents determined by RP-HPLC, and the acceptance limit between 90.0% and 110.0% labeled amount was assigned to ensure the effective and safety levels of preservatives. Last but not least, the microbial limits were also listed in the specifications to control the microbial contamination levels under the acceptance criteria that follows the USP general chapterMicrobiological Examination of Nonsterile Products: Acceptance Criteria for Pharmaceutical Preparations and Substances for Pharmaceutical Use.

The specifications designed for favipiravir oral solution were then used in the formulation screening during the development process, the stability studies for shelf-life and storage condition determinations, and the quality control tests for batch release.
Stability of Favipiravir Oral Solution

The main goal of this study was to develop a sufficiently stable favipiravir formulation for patient use under hospital monitoring, and therefore, a one-month period was considered practical. The physicochemical and microbiological stabilities of our favipiravir oral solution, including the two hospital production lots of CRAFV018 and CRAFV019, were evaluated under four conditions, i.e., 5°C ± 3°C, 25°C ± 2°C/75% RH ± 5% RH, 30°C ± 2°C/75% RH ± 5% RH, and 40°C ± 2°C/75% RH ± 5% RH, in either a refrigerator or a stability chamber. All tests in the specifications, except for identification, were performed. Interestingly, the appearance of our oral solution remained

### Table 3
Specifications of Favipiravir Oral Solution for Hospital Compounding.

| Tests | Acceptance Criteria | Procedure |
|-------|----------------------|-----------|
| 1. Appearance | Clear orange solution with raspberry flavor | Visual inspection |
| 2. Identification | The retention time of the major peak in the chromatogram of the sample solution corresponds to that in the chromatogram of the standard solution, as obtained in the Assay | Validated RP-HPLC USP <621> Chromatography |
| 3. Assay | 95.0 - 105.0% labeled amount of favipiravir (C₅H₄FN₃O₂) | Validated RP-HPLC USP <621> Chromatography |
| 4. Organic impurities | Any individual impurity NMT¹ 1.0% | Validated RP-HPLC USP <621> Chromatography |
| Total impurities | NMT 2.0% | |
| 5. Antimicrobial preservative contents | MPb | Validated RP-HPLC USP <621> Chromatography |
| PPc | 90.0 – 110.0% | |
| 6. pH | 5.80-6.20 | USP <791> pH |
| 7. Microbial limits | TAMBd | USP <61> Microbiological examination of non-sterile products: Microbial enumeration tests |
| TUd | 10⁶ cfu/ml | |
| Escherichia coli | Absent in 1 mL | |

¹ NMT, not more than.
² MP, methylparaben.
³ PP, propylparaben.
⁴ TAMC, total aerobic microbial count.
⁵ TYMC, total yeast and mold count.
⁶ cfu, colony-forming unit.

![Figure 5. Assay (shown as %LA) and individual impurity results from the stability studies of the favipiravir oral solution from Lot No. CRAFV018 and CRAFV019 during up to 60-day storage at 5°C ± 3°C, 25°C ± 2°C/75% RH ± 5% RH, 30°C ± 2°C/75% RH ± 5% RH, and 40°C ± 2°C/75% RH ± 5% RH.](image-url)
B. Tuesuwan et al. / Journal of Pharmaceutical Sciences 112 (2023) 610–617

Table 4

Stability Study of the Favipiravir Oral Solution from Hospital Compounding at 30°C

| Tests                                      | Acceptance Criteria | Lot no. CRAFV018 | Lot no. CRAFV019 |
|--------------------------------------------|---------------------|------------------|------------------|
| 1. Appearance                              | Clear orange solution with raspberry flavor | Complies | Complies |
| 2. Assay                                   | 95.0% ± 3.0%        | NA               | NA               |
| 3. Organic impurities                      | NMT 1.0%            | 101.5 ± 1.1%     | 101.6 ± 1.1%     |
| 4. Antimicrobial preservative contents     | NMT 0.25%           | 5.8 ± 0.2%       | 5.9 ± 0.2%       |
| 5. pH                                      | 5.9–6.0             | 5.9 ± 0.1         | 5.9 ± 0.1        |
| 6. TAMC                                    | < 100 cfu/mL         | Absent           | Absent           |

| Conclusion |

Our collaborative efforts between hospital, academia, and industry have led to a successful development of a favipiravir oral solution in response to an urgent demand for COVID-19 treatments in pediatric patients requiring an alternative dosage form to ease drug administration and improve compliance over that of conventional tablets. Albeit with time constraints during the crisis, we utilized pharmaceutical science concept for formulation development and simplified the manufacturing process for hospital compounding. The quality attributes and specifications of our favipiravir oral solution were justified according to ICH quality guidelines and pharmacopeial monograph to ensure safety and efficacy of the formulation. Stability studies were also performed to determine suitable storage conditions and shelf-life. The finished product from this work has been helping thousands of pediatric patients during COVID-19 outbreak in Thailand.

**Declarations of Interest**

The authors declare no conflict of interest.

**Declaration of Interests**

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

**Acknowledgements**

This work was jointly supported by Chulabhorn Hospital, Chulabhorn Royal Academy, Faculty of Pharmaceutical Sciences,
Chulalongkorn University, and Medica Innova Co., Ltd. We also thank Dr. Mitr Pathipvanich for his review and comments on the formulation studies of this work.

References

1. Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B. 2017;93(7):449–463. https://doi.org/10.2183/pjab.93.027.

2. Avigan Tablets 200 mg. Medical Information Center, Taisho Toyama Pharmaceutical Co., Ltd. 2022. https://www.cdc.gov.tw/File/Get/hb8jld_b_Mi-aKnHwTzvw. Published 2017. Accessed April 15, 2022.

3. Sissoko D, Laouenan C, Folkesson E, et al. Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea. PLOS Med. 2016;13(3): e1001967. https://doi.org/10.1371/journal.pmed.1001967.

4. Bai C-Q, Mu J-S, Kargho D, et al. Clinical and virological characteristics of ebola virus disease patients treated with favipiravir (T-705)-Sierra Leone, 2014. Clin Infect Dis. 2016;63(10):1288–1294. https://doi.org/10.1093/cid/ciw571.

5. Ivashchenko AA, Dmitriev KA, Vostokova N V, et al. AVIFAVIR for treatment of patients with moderate coronavirus disease 2019 (COVID-19): interim results of a phase II/III multicenter randomized clinical trial. Clin Infect Dis. 2021;73(3):531–534. https://doi.org/10.1093/cid/ciaa1176.

6. Manabe T, Kambayashi D, Aikata H, Kudo K. Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis. BMC Infect Dis. 2021;21(1):489. https://doi.org/10.1186/s12879-021-06164-x.

7. Udwastra ZF, Singh P, Barkate H, et al. Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial. Int J Infect Dis. 2021;103:62–71. https://doi.org/10.1016/j.ijid.2020.11.142.

8. Fujii S, Ibe Y, Ishigo T, et al. Early favipiravir treatment was associated with early defervescence in non-severe COVID-19 patients. J Infect Chemother. 2021;27(7):1051–1057. https://doi.org/10.1016/j.jiac.2021.04.013.

9. Karatas E, Aksoy L, Ozaslan E. Association of early favipiravir use with reduced COVID-19 fatality among hospitalized patients. Infect Chemother. 2021;53(2):300–307. https://doi.org/10.3947/ic.2020.0149.

10. Department of Medical Service. Guidelines for Clinical Practice, Diagnosis and Treatment and Prevention of Healthcare-Associated Infection in Response to Patients with COVID-19. Infection. 2022. https://covid19.dms.go.th/Content/Select_Content_Grid_Home_T_8/contentCategoryId=6. Published 2021. Accessed July 15.

11. The international council for harmonisation of technical requirements for pharmaceuticals for human use (ICH). ICH Q6A - Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances1999.

12. The United State Pharmacopeia. 791 - pH. USP-NF2022.

13. The United State Pharmacopeia. 461 Microbiological examination of nonsterile products: microbial enumeration tests. USP-NF2022.

14. The International Council for harmonisation of technical requirements for pharmaceuticals for human use (ICH). ICH Q1A(R2) - Stability Testing of New Drug Substances and Products2003.

15. Japanese Pharmaceuticals and Medical Devices Agency. Report on the Deliberation Results: Avigan Tablet 200 Mg2014. https://www.pmda.go.jp/files/000210319.pdf.

16. Siripongboonsitt T, Ungrtrakul T, Watanaopokasin N, et al. Pharmacokinetic comparison of favipiravir oral solution and tablet formulations in healthy Thai Volunteers. Clin Pharmacol Drug Dev. 2022. https://doi.org/10.1002/cpdd.1149. in press(in press).

17. World Health Organization (WHO). IMWP Monographs on Favipiravir and on Favipiravir Tablets. 2021. https://cdn.who.int/media/docs/default-source/medicines/imwp-favipiravir-monographs.pdf?sfvrsn=212299e1_19&download=true.

18. The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH Q3B (R2) Impurities in New Drug Products2006.

19. The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH M7 Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk – Step 52017.

20. The United State Pharmacopeia. <1111>-Microbiological examination of nonsterile products: acceptance criteria for pharmaceutical preparations and substances for pharmaceutical use. USP-NF2022.

21. Vemuri DK, Gundla R, Konduru N, Mallavarapu R, Katari NK. Favipiravir (SARS-CoV-2) degradation impurities: Identification and route of degradation mechanism in the finished solid dosage form using LC/LC–MS method. Biomed Chromatogr. 2022;36(6):e5363. https://doi.org/10.1002/bmc.5363.